Antibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [6]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11-1389-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD138 (Syndecan-1) Monoclonal Antibody (DL-101), FITC, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The DL-101 monoclonal antibody reacts with human CD138, also known as syndecan-1. CD138 is a transmembrane protein containing chondroitin sulfate and heparin sulfate moieties responsible for binding to the extracellular matrix components. CD138 is not expressed by mature B cells but is present on pre-B cells and the finally differentiated plasma cells. Applications Reported: DL-101 has been reported for use in flow cytometric analysis. Applications Tested: This DL-101 antibody has been pre-titrated and tested by flow cytometric analysis of the U266 cell line. This can be used at 5 µL (1 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Green dye
- Isotype
- IgG
- Antibody clone number
- DL-101
- Vial size
- 100 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection.
Peli1 negatively regulates noncanonical NF-κB signaling to restrain systemic lupus erythematosus.
UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.
Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells.
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
Characterization of B and plasma cells in blood, bone marrow, and secondary lymphoid organs of rhesus macaques by multicolor flow cytometry.
Long-lived plasma cells from human small intestine biopsies secrete immunoglobulins for many weeks in vitro.
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
Akidil E, Albanese M, Buschle A, Ruhle A, Pich D, Keppler OT, Hammerschmidt W
PLoS pathogens 2021 Apr;17(4):e1009117
PLoS pathogens 2021 Apr;17(4):e1009117
Peli1 negatively regulates noncanonical NF-κB signaling to restrain systemic lupus erythematosus.
Liu J, Huang X, Hao S, Wang Y, Liu M, Xu J, Zhang X, Yu T, Gan S, Dai D, Luo X, Lu Q, Mao C, Zhang Y, Shen N, Li B, Huang M, Zhu X, Jin J, Cheng X, Sun SC, Xiao Y
Nature communications 2018 Mar 19;9(1):1136
Nature communications 2018 Mar 19;9(1):1136
UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.
Ezponda T, Dupéré-Richer D, Will CM, Small EC, Varghese N, Patel T, Nabet B, Popovic R, Oyer J, Bulic M, Zheng Y, Huang X, Shah MY, Maji S, Riva A, Occhionorelli M, Tonon G, Kelleher N, Keats J, Licht JD
Cell reports 2017 Oct 17;21(3):628-640
Cell reports 2017 Oct 17;21(3):628-640
Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells.
Schibler J, Tomanek-Chalkley AM, Reedy JL, Zhan F, Spitz DR, Schultz MK, Goel A
PloS one 2016;11(11):e0167323
PloS one 2016;11(11):e0167323
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
Kikuchi J, Koyama D, Wada T, Izumi T, Hofgaard PO, Bogen B, Furukawa Y
The Journal of clinical investigation 2015 Oct 26;125(12):4375-90
The Journal of clinical investigation 2015 Oct 26;125(12):4375-90
Characterization of B and plasma cells in blood, bone marrow, and secondary lymphoid organs of rhesus macaques by multicolor flow cytometry.
Neumann B, Klippert A, Raue K, Sopper S, Stahl-Hennig C
Journal of leukocyte biology 2015 Jan;97(1):19-30
Journal of leukocyte biology 2015 Jan;97(1):19-30
Long-lived plasma cells from human small intestine biopsies secrete immunoglobulins for many weeks in vitro.
Mesin L, Di Niro R, Thompson KM, Lundin KE, Sollid LM
Journal of immunology (Baltimore, Md. : 1950) 2011 Sep 15;187(6):2867-74
Journal of immunology (Baltimore, Md. : 1950) 2011 Sep 15;187(6):2867-74
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA
Blood 2010 Sep 30;116(13):2286-94
Blood 2010 Sep 30;116(13):2286-94
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of the U266 cell line with Mouse IgG1 K Isotype Control FITC (Product # 11-4714-42) (blue histogram) or Anti-Human CD138 (Syndecan-1) FITC (purple histogram). Total viable cells, as determined by Fixable Viability Dye eFluor® 660, were used for analysis.
- Conjugate
- Green dye
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig 4 p16 INK4a is a functional barrier to EBV driven proliferation of lymphoblastoid cells. (A) Blueprint of the primary transcript and the spliced mRNA with the three exons of CDKN2A on chromosome 9 encoding the p16 INK4a protein. The target site of the RNP complex within the 1st exon (exon1alpha) (chr9:21,974,678-21,974,827) is shown. (B) Study of the biological effect of the CDKN2A knockout in a time course experiment. WT and p16 KO cells were mixed such that the fraction of the latter was in the order of 10 to 20%, when the cells were infected with WT or DeltaEBNA3C EBV strains. The knockout status of the CDKN2A gene was studied by next generation sequencing to analyze the CD46 locus of the mixed cell populations over time. The fraction of cells with a disabled CDKN2A gene increased in cells infected with DeltaEBNA3C EBV exceeding 80% after eight weeks, whereas the knockout status of CDKN2A in the population of cells infected with WT EBV did not show a clear trend. Results from two biological replicates are shown, additional replicates can be found in S4A Fig . (C) Cell numbers of four different B cell populations were plotted as a function of days post nucleofection (x-axis) versus the format of the cell culture vessel (y-axis) starting with a single well in a 48-well cluster plate. 2x10 6 B cells with an intact CDKN2A locus (WT cells) or cells with an edited CDKN2A gene (p16 KO cells) were infected with wild-type (WT) EBV (left panel) or DeltaEBNA3C EBV (right panel).
- Conjugate
- Green dye